Minor histocompatibility antigens as targets of graft-versus-leukemia reactions.
The main advantage of allogeneic stem cell transplantation over autologous stem cell transplantation for hematologic malignancies is the ability to perform cellular immunotherapy using donor-derived immune effector cells after transplantation. In HLA-matched allogeneic stem cell transplantation, the beneficial graft-versus-leukemia effect of donor lymphocytes appears to be caused mainly by alloreactive T cells that are capable of recognizing minor histocompatibility antigens on the malignant cell population from the patient. The tissue distribution of minor histocompatibility antigens probably determines the clinical result of T-cell responses against these antigens. Whereas T cells recognizing broadly expressed antigens cause not only graft-versus-leukemia but also graft-versus-host disease, T cells recognizing minor histocompatibility antigens specifically expressed on hematopoietic cells may mainly eliminate hematopoietic cells from the recipient, including the malignant cells, without affecting donor hematopoiesis or normal nonhematopoietic tissues. Graft-versus-host disease may still occur because of the induction of inflammatory responses against hematopoietic cells in the tissues. Vaccination of patients after transplantation or vaccination of stem cell donors before transplantation using minor histocompatibility antigen-specific peptides, production of minor histocompatibility antigen-specific T cells, and redirection of T-cell specificity by gene transfer of T-cell receptors may be strategies to eradicate specifically the malignant cells after allogeneic stem cell transplantation.
Falkenburg
J H F
JH
Department of Hematology, Leiden University Medical Center, The Netherlands. falkenburg,hematology@lumc.nl
Marijt
W A F
WA
Heemskerk
M H M
MH
Willemze
R
R
D000951:Antigens, Neoplasm / Q000276:immunology / Q000627:therapeutic use; D020544:Graft vs Leukemia Effect / Q000276:immunology*; D019337:Hematologic Neoplasms / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D017710:Lymphocyte Transfusion; D015778:Minor Histocompatibility Antigens / Q000276:immunology / Q000627:therapeutic use*; D014184:Transplantation, Homologous / Q000276:immunology / Q000379:methods
D000951:Antigens, Neoplasm; D015778:Minor Histocompatibility Antigens